GlaxoSmithKline, CureVac and BioNTech clinch German pandemic preparedness contracts

As CureVac and GlaxoSmithKline mulligan with a second-generation COVID-19 vaccine, the partners have signed on for a German pandemic contingency plan to earmark mRNA production capacity for years to come.

The contract with the German federal government will see GSK and CureVac supply mRNA vaccines “within a broader tender for pandemic preparedness in Germany." After a maximum two-year setup period, the companies will provide the German government with access to CureVac’s manufacturing capacity until 2029.